Scientistscome up empty—no viable CAR T metastatic cells to test CAR T-cell therapies
For the first time, scientists have tested their experimental CAR T-cell therapy technique and were able to successfully treat leukemia patients without cellular toxicity—evidence that may enable tests in more other cancer types. The research was led by Christoph Becker, Ph. D., director of the Division of Tumor Biology and a member of the Cancer Nutrition and Cancer Research Institute at the University of Copenhagen. The research has been published in Cell Reports.
CAR T-cell therapy is a treatment in which a patient’s cancer is killed by immune cells attacking resident or foreign cells. Its use to treat multiple myeloma and acute lymphoblastic leukemia, among others, has produced promising results. CAR T therapy is based on transforming growth factor beta, which is, among other things, an important factor in the need for T-cell therapy.